Ischemia Reperfusion Injury Therapeutics Market, By Treatment, By Injury, By End User, and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	233 Pages	Coherent Market Insights	March, 2025	CMI20007889

Best Price Guarantee
Price	from $4,500
Length	233 Pages
Publisher	Coherent Market Insights
Published Date	March, 2025
SKU	CMI20007889

Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of an ischemia injury include bradycardia, headache, hypertension, and seizures. Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians.

Market Dynamics

Increasing number of research and development activities by the key market players for the treatment of patients suffering from reperfusion injury is expected to drive the growth of market over the forecast period. For instance, on May 31, 2022, GNT Pharma, a pharmaceutical company,reported that Nelonemdaz is under clinical for phase I clinical trial. Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction.

Furthermore, in September 2021, GNT Pharma, a pharmaceutical company, reported that the Korea Ministry of Food and Drug Safety (MFDS) had approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma’s earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.

Key features of the study:

This report provides an in-depth analysis of the global ischemia reperfusion injury therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Revive Therapeutics Ltd., Faraday Pharmaceuticals, Abiomed, Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Ischemia Reperfusion Injury Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ischemia reperfusion injury therapeutics market

Detailed Segmentation:

Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment:
Drug Therapy
Medicated Gas
Others (Vitamin Therapy and among Others)
Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury (Brain Injuries and Among Others)
Global Ischemia Reperfusion Injury Therapeutics Market, By End user:
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others(Academic and Research Institutes and among Others)
Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Revive Therapeutics Ltd.
Faraday Pharmaceuticals
Abiomed
Omeros Corporation
Pharming Group N.V.
Nyken B.V.
Orexo AB
Opsona Therapeutics Limited
PledPharma AB
Prothix BV
Proteo, Inc.
Amyndas Pharmaceuticals LLC
Prolong Pharmaceuticals
Stealth BioTherapeutics Inc.
Zealand Pharma A/S
Antipodean Pharmaceuticals, Inc.
Bayer AG
Angion Biomedica Corp.
Bolder Biotechnology, Inc.
Curatis Pharma GmbH
Biomedica Management Corporation
Ensemble Therapeutics Corporation
Gilead Sciences, Inc.
Erimos Pharmaceuticals, LLC.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Treatment; Market Snapshot, By Injury Type; Market Snapshot, By End user; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Product Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis; Partnership Scenario; Brand and Pricing Analysis; Distributors Landscape; Porters Analysis; Technological Advancements; Key Developments; Market Trend; Top Market Players by Revenue
4. Global Ischemia Reperfusion Injury Therapeutics Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment, 2020–2032, (US$ Billion): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Drug Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends; Medicated Gas; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends; Others (Vitamin Therapy and among Others); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends
6. Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type, 2020–2032, (US$ Billion): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Heart Injury; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends; Kidney Injury; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends; Intestine Injury; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends; Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Segment Trends
7. Global Ischemia Reperfusion Injury Therapeutics Market, By End user, 2020–2032, (US$ Billion): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Hospitals; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Specialty Clinics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Ambulatory Surgical Centers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion); Others (Academic and Research Institutes and among Others); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Billion)
8. Global Ischemia Reperfusion Injury Therapeutics Market, By Region, 2020–2032, (US$ Billion): Introduction; Market Share Analysis, By Region, 2025 and 2032 (%); Y-o-Y Growth Analysis, For Regions, 2021–2032; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2020–2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (US$ Billion); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2020–2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Billion); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020- 2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2020–2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Billion); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2020–2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Billion); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2020–2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020– 2032, (US$ Billion); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2020-2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End user, 2020–2032, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Billion); North Africa; Central Africa; South Africa
9. Competitive Landscape: Revive Therapeutics Ltd.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Faraday Pharmaceuticals; Abiomed; Omeros Corporation; Pharming Group N.V.; Nyken B.V.; Orexo AB; Opsona Therapeutics Limited; PledPharma AB; Prothix BV; Proteo, Inc.; Amyndas Pharmaceuticals LLC; Prolong Pharmaceuticals; Stealth BioTherapeutics Inc.; Zealand Pharma A/S; Antipodean Pharmaceuticals, Inc.; Bayer AG; Angion Biomedica Corp.; Bolder Biotechnology, Inc.; Curatis Pharma GmbH; Biomedica Management Corporation; Ensemble Therapeutics Corporation; Gilead Sciences, Inc.; Erimos Pharmaceuticals, LLC.
10. Section: Research Methodology; About Us; *Browse 43 market data tables and 39 figures on “Ischemia Reperfusion Injury Therapeutics Market”- forecast to 2032